Akèy › Kansè lestomak › Texas › Austin
Etid klinik pou Kansè lestomak nan Austin, TX
10 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Austin
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- Texas Oncology-Austin Central, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Texas Oncology (Balcones) - SCRI, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- NEXT Oncology - Austin, Austin
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- NEXT Austin, Austin
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Texas Oncology - Central South, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- NEXT Oncology Austin /ID# 243005, Austin
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Ap rekriteFaz 3
- Texas Oncology Central South (SCRI), Austin
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Elligo Health Research, Inc., Austin
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Austin
Etid Kansè lestomak nan lòt vil
- Houston, TX42 etid
- Boston, MA32 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA22 etid
- Baldwin Park, CA22 etid
- Arlington, VA20 etid
- Dallas, TX19 etid
- San Antonio, TX19 etid
- Grand Rapids, MI18 etid
- St. Louis, MO18 etid
- Washington, DC16 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)20 etid
- Obèsite20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal19 etid
- Ensifizyans kadyak18 etid
- Kansè nan tete18 etid
- Sipwa18 etid
- Kansè ovè17 etid
- Kansè Endomèt15 etid
- Kansè pwostat15 etid
- Depresyon14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.